连续肾脏替代治疗与体外膜氧合不同连接方案对动脉压和静脉压的影响:一项体外与体内研究
该研究通过体外模拟6种CRRT与ECMO连接方案(A-F),在2-5.5 L/min不同ECMO血流量下测量PA、PV和TMP,并回顾性分析10例因PA或PV过高而更换连接方案(A或B改为E或F)的患者。体外显示E、F方案PV绝对值最低且TMP在正常范围,C、D方案在高流量时TMP为负提示透析液反滤。体内10例患者更换方案后PA由257.20±21.92 mmHg降至244.00±22.58 mmHg,PV由326.40±15.41 mmHg降至257.20±18.43 mmHg(均P<0.01),PV下降幅度大于PA(69.20±6.55 mmHg vs. 13.20±5.45 mmHg,P<0.01)。作者认为该连接方案可显著降低PA和PV并维持高流量ECMO下CRRT正常运行。
要点
- 体外实验中,方案E、F(CRRT引血端接氧合器前或后、回血端接回流导管处)的PV绝对值最低,是更合理的连接方案。
- 方案C、D在ECMO血流量5 L/min和5.5 L/min时TMP为负值(5 L/min:C为-29.14±11.42 mmHg,D为-42.45±15.70 mmHg;5.5 L/min:C为-35.75±13.21 mmHg,D为-41.58±15.42 mmHg),提示存在透析液反滤。
- 体内10例因PA或PV过高将方案A或B改为E或F后,PA由257.20±21.92 mmHg降至244.00±22.58 mmHg,PV由326.40±15.41 mmHg降至257.20±18.43 mmHg,均P<0.01。
- 更换方案后PV下降幅度大于PA(差值69.20±6.55 mmHg vs. 13.20±5.45 mmHg,P<0.01)。
- 方案A、B在体外高流量时部分PA>300 mmHg,方案C、D在高流量时部分PV>350 mmHg,方案E、F更为合理。
适用人群与场景
- 接受ECMO联合CRRT治疗的患者,体内研究纳入10例因PA或PV过高而更换连接方案者,其中男性8例、女性2例,VA-ECMO 7例、VV-ECMO 3例,均使用CVVHDF模式。
诊断标准与关键阈值
- 体外研究按CRRT与ECMO管路连接位置分为6种方案:A为氧合器前后两点;B为氧合器后和前两点;C为氧合器前和离心泵前两点;D为氧合器后和离心泵前两点;E为氧合器前和回流导管处;F为氧合器后和回流导管处。
- 体外研究在ECMO血流量2、3、4、5、5.5 L/min下测量,每套ECMO管路每种连接方案测量5次,共6套ECMO管路合计30次测量。
处置流程与药物剂量
- 体外研究显示方案E、F较方案A、B、C、D更合理:方案A、B在高流量时部分PA>300 mmHg,方案C、D在高流量时部分PV>350 mmHg,而方案E、F的PV绝对值最低。
- 体内研究中,因PA或PV过高将连接方案从A或B改为E或F后,PA和PV均显著下降(均P<0.01),且PV下降幅度大于PA(P<0.01)。
红旗征与不能漏的情况
- 方案C、D在ECMO血流量5 L/min和5.5 L/min时TMP为负值(5 L/min:C为-29.14±11.42 mmHg,D为-42.45±15.70 mmHg;5.5 L/min:C为-35.75±13.21 mmHg,D为-41.58±15.42 mmHg),提示存在透析液反滤。
- 方案A、B在高流量时部分PA>300 mmHg,方案C、D在高流量时部分PV>350 mmHg。
研究设计与关键结果
- 体外研究:不同ECMO血流量(2-5.5 L/min)下,方案A与B、C与D、E与F之间PA无显著差异;方案C、D的PA最低,其次为方案E、F;方案B的PV高于方案A;高流量(3-5.5 L/min)下方案C与D、E与F之间PV无显著差异,方案E、F的PV绝对值最低。
- 体外研究:方案A、B、E、F在不同ECMO血流量(2-5.5 L/min)下TMP差异多数有统计学意义,平均波动绝对值9.89-49.55 mmHg,均在正常范围内。
- 体内研究:共纳入10例更换连接方案(从A或B改为E或F)的患者,其中男性8例、女性2例;VA-ECMO 7例,VV-ECMO 3例,均使用CVVHDF模式。
- 体内研究:更换方案后PA和PV均较更换前显著下降[PA(mmHg):244.00±22.58 vs. 257.20±21.92,PV(mmHg):257.20±18.43 vs. 326.40±15.41,均P<0.01],且PV下降幅度大于PA[差值(mmHg):69.20±6.55 vs. 13.20±5.45,P<0.01]。
证据类型、等级与局限
- 研究类型:体外模拟实验联合单中心回顾性分析(2017年8月至2021年8月皖南医学院第一附属医院重症医学科)。
- 样本量:体外6套ECMO管路共30次测量;体内10例患者。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对于ECMO联合CRRT治疗的患者,将CRRT引血端连接至氧合器前或后、回血端连接至回流导管处(即方案E或F),可显著降低PA和PV,并在高流量ECMO运行时仍能维持CRRT正常运转。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the effects of different connection schemes of continuous renal replacement therapy (CRRT) and extracorporeal membrane oxygenation (ECMO) on arterial pressure (PA), venous pressure (PV), and transmembrane pressure (TMP), and to provide a theoretical basis for choosing a suitable connection scheme.
METHODS: (1) In vitro study: the different connection schemes of CRRT and ECMO were simulated and divided into 6 schemes according to the connection between CRRT and ECMO circuits at different positions. Scheme A: connected to the front and back points of the oxygenator; scheme B: connected to the points behind and in front of the oxygenator; scheme C: connected to the points in front of the oxygenator and in front of the centrifugal pump; scheme D: connected to the points behind the oxygenator and in front of the centrifugal pump; scheme E: connected to the points in front of the oxygenator and the return catheter; scheme F: connected to the points after the oxygenator and the return catheter. Each set of ECMO circuits was measured 5 times under each connection scheme and different flow rates (2, 3, 4, 5, 5.5 L/min). Six ECMO circuits for a total of 30 measurements, and the PA, PV, and TMP of the 6 schemes were compared. (2) In vivo study: the patients who were treated with ECMO combined with CRRT in the department of critical care medicine of the First Affiliated Hospital of Wannan Medical College from August 2017 to August 2021 changed the connection scheme due to high PA or PV (from scheme A or B to scheme E or F) were retrospectively analyzed. The changes of PA and PV before and after changing the scheme were compared.
RESULTS: (1) In vitro study results: there was no significant difference in PA between schemes A and B, C and D, E and F under different ECMO blood flow (2-5.5 L/min). The PA of schemes C and D was the lowest, followed by schemes E and F. PV of scheme B was higher than that of scheme A under different ECMO blood flow (2-5.5 L/min). There was no significant difference in PV between schemes C and D, E and F under high ECMO blood flow (3-5.5 L/min), and the absolute value of PV was lowest in schemes E and F. Compared with schemes A and B [partial PA > 300 mmHg (1 mmHg ≈ 0.133 kPa) at high flow rate], C and D (partial PV > 350 mmHg at high flow rate), schemes E and F were more reasonable connection schemes. TMP was negative in schemes C and D at ECMO blood flow of 5 L/min and 5.5 L/min (mmHg; 5 L/min: scheme C was -29.14±11.42, scheme D was -42.45±15.70; 5.5 L/min: scheme C was -35.75±13.21, scheme D was -41.58±15.42), which indicated the presence of dialysate reverse filtration. Most of the differences in TMP among schemes A, B, E, and F under different ECMO blood flow (2-5.5 L/min) were statistically significant, and the absolute value of mean fluctuation was 9.89-49.55 mmHg, all within the normal range. (2) In vivo study results: a total of 10 patients who changed the connection scheme (from scheme A or B to E or F) due to high PA or PV were enrolled, including 8 males and 2 females; 7 cases of venous-arterial ECMO (VA-ECMO) and 3 cases of venous-venous ECMO (VV-ECMO), all used continuous veno-venous hemodiafiltration (CVVHDF) mode. After changing the scheme, both PA and PV decreased significantly as compared with those before changing [PA (mmHg): 244.00±22.58 vs. 257.20±21.92, PV (mmHg): 257.20±18.43 vs. 326.40±15.41, both P < 0.01], and PV decreased more significantly than PA [difference (mmHg): 69.20±6.55 vs. 13.20±5.45, P < 0.01].
CONCLUSION: For patients treated with ECMO in combination with CRRT, the scheme of connecting the access line of CRRT to the pre-oxygenator or post-oxygenator and connecting the return line to the point of the return catheter can significantly reduce PA and PV and maintains normal CRRT operation even running high-flow ECMO.
参考来源
- Wang J, Xu Q, Li J, et al. [Effect of different connection schemes of continuous renal replacement therapy and extracorporeal membrane oxygenation on arterial and venous pressure: an in vitro and in vivo study]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 35692204. doi:10.3760/cma.j.cn121430-20210824-01261
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。